Over the last quarter century, we have witnessed the emergence of a diverse portfolio of biotech drug modalities, ranging from recombinant proteins to cell and tissue therapies. In general, there is a trend toward growing drug complexity, following the deeper understanding of disease biology. While the biochemical engineering concepts employed in the manufacturing of these modalities reflect this diversity, significant benefits have been gained through development of bioprocessing platforms with broader applicability. This presentation will focus on the potential of exosome-based therapeutics, a new modality that has witnessed tremendous progress over the last few years. The bioprocess and analytical technologies for their future commercialization will be discussed in the context of the capabilities and limitations of the existing biomanufacturing platforms
